$GOVX
GeoVax Labs, Inc.

2023 Q3 Form 10-Q Financial Statement

#000143774923022775 Filed on August 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.650M $1.459M
YoY Change 32.07% 55.99%
% of Gross Profit
Research & Development $6.948M $4.720M
YoY Change 155.33% 261.06%
% of Gross Profit
Depreciation & Amortization $20.00K $17.32K
YoY Change 13.19% 41.16%
% of Gross Profit
Operating Expenses $8.600M $6.179M
YoY Change 116.59% 175.53%
Operating Profit -$8.600M -$6.179M
YoY Change 116.59% 175.53%
Interest Expense $190.0K $251.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net $190.9K $251.2K
YoY Change 7754.22% 31737.9%
Pretax Income -$8.410M -$5.928M
YoY Change 111.94% 164.44%
Income Tax
% Of Pretax Income
Net Earnings -$8.409M -$5.928M
YoY Change 111.91% 164.43%
Net Earnings / Revenue
Basic Earnings Per Share -$0.32 -$0.22
Diluted Earnings Per Share -$0.32 -$0.22
COMMON SHARES
Basic Shares Outstanding 26.44M 26.44M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.69M $17.79M
YoY Change -63.41% -42.44%
Cash & Equivalents $12.69M $17.79M
Short-Term Investments
Other Short-Term Assets $2.110M $2.038M
YoY Change 44.5% 79.46%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $14.80M $19.83M
YoY Change -59.04% -38.11%
LONG-TERM ASSETS
Property, Plant & Equipment $213.0K $224.1K
YoY Change -14.47% 4.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.188M $1.198M
YoY Change -45.62% 21.29%
Total Long-Term Assets $1.401M $1.422M
YoY Change -42.43% 18.26%
TOTAL ASSETS
Total Short-Term Assets $14.80M $19.83M
Total Long-Term Assets $1.401M $1.422M
Total Assets $16.20M $21.25M
YoY Change -58.0% -36.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.213M $871.1K
YoY Change 290.33% 267.08%
Accrued Expenses $2.868M $3.214M
YoY Change -22.68% 2.68%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.082M $4.086M
YoY Change 47.86% 21.31%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.082M $4.086M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $7.080M $4.086M
YoY Change 4.28% -23.89%
SHAREHOLDERS EQUITY
Retained Earnings -$96.77M -$88.36M
YoY Change 32.54% 27.98%
Common Stock $105.9M $105.5M
YoY Change 1.05% 8.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.119M $17.16M
YoY Change
Total Liabilities & Shareholders Equity $16.20M $21.25M
YoY Change -58.0% -36.07%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$8.409M -$5.928M
YoY Change 111.91% 164.43%
Depreciation, Depletion And Amortization $20.00K $17.32K
YoY Change 13.19% 41.16%
Cash From Operating Activities -$5.100M -$6.037M
YoY Change 34.24% 57.48%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $23.81K
YoY Change -119.28% -217.93%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K -$23.81K
YoY Change -80.72% 17.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -5.100M -6.037M
Cash From Investing Activities -10.00K -23.81K
Cash From Financing Activities 0.000 0.000
Net Change In Cash -5.110M -6.061M
YoY Change -235.38% -141.39%
FREE CASH FLOW
Cash From Operating Activities -$5.100M -$6.037M
Capital Expenditures $10.00K $23.81K
Free Cash Flow -$5.110M -$6.061M
YoY Change 36.37% 58.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26443649
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26443649
dei Entity Central Index Key
EntityCentralIndexKey
0000832489
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
4361704 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9229248 usd
CY2022Q1 govx Stock Issued During Period Value Warrant Exercise
StockIssuedDuringPeriodValueWarrantExercise
24 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
190191 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2427515 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11353652 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18497946 usd
CY2022Q2 govx Stock Issued During Period Value Warrant Exercise
StockIssuedDuringPeriodValueWarrantExercise
567 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
72000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
190191 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2241699 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
27872657 usd
us-gaap Net Income Loss
NetIncomeLoss
-9965536 usd
us-gaap Net Income Loss
NetIncomeLoss
-4669214 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
34637 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
24538 usd
us-gaap Share Based Compensation
ShareBasedCompensation
515552 usd
us-gaap Share Based Compensation
ShareBasedCompensation
412329 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-0 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-49006 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
698785 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
939487 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-976498 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
976498 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-662382 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2067492 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
165520 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-3497604 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9800016 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8166818 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
23805 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
82383 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23805 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-82383 usd
govx Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0 usd
govx Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
27727194 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
591 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27727785 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9823821 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19478584 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27612732 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11423870 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17788911 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30902454 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
865222 usd
us-gaap Nature Of Operations
NatureOfOperations
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>1.</b> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Nature of Business </b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax Labs, Inc., headquartered in the Atlanta, Georgia metropolitan area, is a clinical-stage biotechnology company incorporated under the laws of the State of Delaware. GeoVax Labs, Inc. and its wholly owned subsidiary, GeoVax, Inc., a Georgia corporation, are collectively referred to herein as “GeoVax” or the “Company”.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company is focused on developing immunotherapies and vaccines against cancers and infectious diseases using novel vector vaccine platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy for advanced head and neck cancer. Additional preclinical research and development programs include preventive vaccines against Mpox (monkeypox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa Fever) Zika virus, and malaria, as well as immunotherapies for solid tumors.</p>
CY2023Q2 govx Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
1941588 usd
CY2022Q4 govx Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
1171077 usd
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
36150 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
107876 usd
CY2023Q2 us-gaap Prepaid Rent
PrepaidRent
13045 usd
CY2022Q4 us-gaap Prepaid Rent
PrepaidRent
13045 usd
CY2023Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
47500 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
34000 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2038283 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1325998 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
841417 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
641142 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
606505 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
224080 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
234912 usd
CY2023Q2 govx Prepaid Clinical Trial Expenses Noncurrent
PrepaidClinicalTrialExpensesNoncurrent
1106778 usd
CY2022Q4 govx Prepaid Clinical Trial Expenses Noncurrent
PrepaidClinicalTrialExpensesNoncurrent
2083276 usd
CY2023Q2 govx Prepaid Technology License Fees
PrepaidTechnologyLicenseFees
80000 usd
CY2022Q4 govx Prepaid Technology License Fees
PrepaidTechnologyLicenseFees
80000 usd
CY2023Q2 us-gaap Security Deposit
SecurityDeposit
11010 usd
CY2022Q4 us-gaap Security Deposit
SecurityDeposit
11010 usd
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1197788 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2174286 usd
CY2023Q2 govx Accrued License Fees Current
AccruedLicenseFeesCurrent
2000000 usd
CY2022Q4 govx Accrued License Fees Current
AccruedLicenseFeesCurrent
2000000 usd
CY2023Q2 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
123922 usd
CY2022Q4 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
550810 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
1090459 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
449402 usd
CY2023Q2 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
3214381 usd
CY2022Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
3000212 usd
CY2023Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
108696
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
13384115
CY2023Q2 govx Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
2.77
CY2023Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P4Y
CY2023Q2 govx Prepaid Expense Value Of Stock Issued For Services During Period
PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod
37500 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15406248
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18967629

Files In Submission

Name View Source Status
0001437749-23-022775-index-headers.html Edgar Link pending
0001437749-23-022775-index.html Edgar Link pending
0001437749-23-022775.txt Edgar Link pending
0001437749-23-022775-xbrl.zip Edgar Link pending
ex_554829.htm Edgar Link pending
ex_554830.htm Edgar Link pending
ex_554831.htm Edgar Link pending
ex_554832.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
govx-20230630.xsd Edgar Link pending
govx20230630_10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
govx-20230630_cal.xml Edgar Link unprocessable
govx-20230630_lab.xml Edgar Link unprocessable
govx-20230630_pre.xml Edgar Link unprocessable
govx20230630_10q_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
govx-20230630_def.xml Edgar Link unprocessable